Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review

Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:OncoTargets and therapy 2020-01, Vol.13, p.3319-3324
Hauptverfasser: Su, Xiangyu, Zhang, Jing, Fu, Chenchun, Xiao, Mingzhe, Wang, Cailian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3324
container_issue
container_start_page 3319
container_title OncoTargets and therapy
container_volume 13
creator Su, Xiangyu
Zhang, Jing
Fu, Chenchun
Xiao, Mingzhe
Wang, Cailian
description Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months. This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.
doi_str_mv 10.2147/OTT.S231258
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7183339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32368090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</originalsourceid><addsrcrecordid>eNpVUctOwzAQtBCIR-HEHfmOAnacxCkHJCivSkWN2nKOHGfTGjVOZDsFfoZvxVVLBYfVrmZmZ7UahM4puQppxK_Hs9nVNGQ0jNM9dEwpT4Okz8j-n_kInVj7TkiSpGF0iI5YyJKU9Mkx-p6A7IwB7fArOGGdcEriDLRaAh4ILcHgzGNrwYdyC5w1Vjm1Apw9BCOKHz9bA9aqRuNx4YTSUOKpmmtVKSn8zj1oqJTDlWlqPKzrTjduAUa0Xzf4zh-wgCfQNsZhoUs8Us5zrjNrdKXg4xQdVGJp4Wzbe-jt6XE2eAlG4-fh4G4USBalLgDJiopKwgsZMUFiQmlMijJKfIWl5EXBRShlJWPBRVnSPoEwoSWNOReRV7Ieut34tl1RQyn9u0Ys89aoWpivvBEq_89otcjnzSrnNGWM9b3B5cZAmsZaA9Vul5J8HVPuY8q3MXn1xd9zO-1vLuwHY7OSgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</title><source>Taylor &amp; Francis Open Access</source><source>DOVE Medical Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Su, Xiangyu ; Zhang, Jing ; Fu, Chenchun ; Xiao, Mingzhe ; Wang, Cailian</creator><creatorcontrib>Su, Xiangyu ; Zhang, Jing ; Fu, Chenchun ; Xiao, Mingzhe ; Wang, Cailian</creatorcontrib><description>Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months. This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S231258</identifier><identifier>PMID: 32368090</identifier><language>eng</language><publisher>New Zealand: Dove</publisher><subject>Case Report</subject><ispartof>OncoTargets and therapy, 2020-01, Vol.13, p.3319-3324</ispartof><rights>2020 Su et al.</rights><rights>2020 Su et al. 2020 Su et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</citedby><cites>FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</cites><orcidid>0000-0001-6027-3543</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183339/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183339/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3860,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32368090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Xiangyu</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Fu, Chenchun</creatorcontrib><creatorcontrib>Xiao, Mingzhe</creatorcontrib><creatorcontrib>Wang, Cailian</creatorcontrib><title>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months. This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.</description><subject>Case Report</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUctOwzAQtBCIR-HEHfmOAnacxCkHJCivSkWN2nKOHGfTGjVOZDsFfoZvxVVLBYfVrmZmZ7UahM4puQppxK_Hs9nVNGQ0jNM9dEwpT4Okz8j-n_kInVj7TkiSpGF0iI5YyJKU9Mkx-p6A7IwB7fArOGGdcEriDLRaAh4ILcHgzGNrwYdyC5w1Vjm1Apw9BCOKHz9bA9aqRuNx4YTSUOKpmmtVKSn8zj1oqJTDlWlqPKzrTjduAUa0Xzf4zh-wgCfQNsZhoUs8Us5zrjNrdKXg4xQdVGJp4Wzbe-jt6XE2eAlG4-fh4G4USBalLgDJiopKwgsZMUFiQmlMijJKfIWl5EXBRShlJWPBRVnSPoEwoSWNOReRV7Ieut34tl1RQyn9u0Ys89aoWpivvBEq_89otcjnzSrnNGWM9b3B5cZAmsZaA9Vul5J8HVPuY8q3MXn1xd9zO-1vLuwHY7OSgQ</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Su, Xiangyu</creator><creator>Zhang, Jing</creator><creator>Fu, Chenchun</creator><creator>Xiao, Mingzhe</creator><creator>Wang, Cailian</creator><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6027-3543</orcidid></search><sort><creationdate>20200101</creationdate><title>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</title><author>Su, Xiangyu ; Zhang, Jing ; Fu, Chenchun ; Xiao, Mingzhe ; Wang, Cailian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Su, Xiangyu</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Fu, Chenchun</creatorcontrib><creatorcontrib>Xiao, Mingzhe</creatorcontrib><creatorcontrib>Wang, Cailian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Xiangyu</au><au>Zhang, Jing</au><au>Fu, Chenchun</au><au>Xiao, Mingzhe</au><au>Wang, Cailian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>13</volume><spage>3319</spage><epage>3324</epage><pages>3319-3324</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months. This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.</abstract><cop>New Zealand</cop><pub>Dove</pub><pmid>32368090</pmid><doi>10.2147/OTT.S231258</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6027-3543</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2020-01, Vol.13, p.3319-3324
issn 1178-6930
1178-6930
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7183339
source Taylor & Francis Open Access; DOVE Medical Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Case Report
title Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T03%3A07%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrent%20Metastatic%20Penile%20Cancer%20Patient%20with%20Positive%20PD-L1%20Expression%20Obtained%20Significant%20Benefit%20from%20Immunotherapy:%20A%20Case%20Report%20and%20Literature%20Review&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Su,%20Xiangyu&rft.date=2020-01-01&rft.volume=13&rft.spage=3319&rft.epage=3324&rft.pages=3319-3324&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S231258&rft_dat=%3Cpubmed_cross%3E32368090%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32368090&rfr_iscdi=true